Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.85−0.15 (-5.15%)
Close on Nov 18, 2026Market cap $304.54MP/E –Yield –
Relmada Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Relmada Therapeutics's free cash flow for the twelve months ending Jun 30, 2018 was -$6.01M. For fiscal 2018 it was -$6.01M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | -$6.01M | – |
| FY2017 | Jun 30, 2017 | -$6.52M | – |
| FY2016 | Jun 30, 2016 | -$13.71M | – |
| FY2013 | Dec 31, 2013 | -$2.25M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$2.28M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$1.63M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$1.13M | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$981.64K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$1.02M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$1.88M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$1.45M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$2.17M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$2.85M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$3.69M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$3.95M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -$3.22M | – |
| Q3 FY2013CQ3 2013 | Sep 30, 2013 | -$409.46K | – |
See a number that looks wrong?